Circulating Tumor DNA as Biomarkers for Cancer Detection

Genomics, Proteomics and Bioinformatics

Volumn 15, Issue 2, 2017, Pages 59-72

  Han, Xiao ^a,b   Wang, Junyun ^a   Sun, Yingli ^a  

^a Chinese Academy of Sciences   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Biomarker; Cell free nucleic acids; Circulating tumor DNA; Clinical diagnosis; Liquid biopsy; Precision medicine

Indexed keywords

BIOLOGICAL MARKER; CIRCULATING TUMOR DNA; DNA; UNCLASSIFIED DRUG; TUMOR MARKER;

BREAST CANCER; CANCER DIAGNOSIS; CANCER GENETICS; CANCER PATIENT; CANCER PROGNOSIS; COLORECTAL CANCER; DNA METHYLATION; EARLY CANCER DIAGNOSIS; EPIGENETICS; GENE MUTATION; HUMAN; NON INVASIVE PROCEDURE; NON SMALL CELL LUNG CANCER; PERSONALIZED MEDICINE; REVIEW; FEMALE; GENETICS; MALE; NEOPLASMS; PROCEDURES;

BIOMARKERS, TUMOR; DNA, NEOPLASM; FEMALE; HUMANS; MALE; NEOPLASMS; PRECISION MEDICINE;

EID: 85018551150     PISSN: 16720229     EISSN: 22103244     Source Type: Journal    
DOI: 10.1016/j.gpb.2016.12.004     Document Type: Review

References (196)

1. [1] McGuire, S., World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr 7 (2016), 418–419.
2. [2] Dainiak, N., Inferences, risk modeling, and prediction of health effects of ionizing radiation. Health Phys 110 (2016), 271–273.
3. [3] Zhou, D.D., Hao, J.L., Guo, K.M., Lu, C.W., Liu, X.D., Sperm quality and DNA damage in men from Jilin Province, China, who are occupationally exposed to ionizing radiation. Genet Mol Res, 15, 2016, gmr8078.
4. [4] Chaudhuri, A.A., Binkley, M.S., Osmundson, E.C., Alizadeh, A.A., Diehn, M., Predicting radiotherapy responses and treatment outcomes through analysis of circulating tumor DNA. Semin Radiat Oncol 25 (2015), 305–312.
5. [5] Martin, N.E., D'Amico, A.V., Progress and controversies: radiation therapy for prostate cancer. CA Cancer J Clin 64 (2014), 389–407.
6. [6] Mancebo, S.E., Wang, S.Q., Skin cancer: role of ultraviolet radiation in carcinogenesis. Rev Environ Health 29 (2014), 265–273.
7. [7] Ignatiadis, M., Lee, M., Jeffrey, S.S., Circulating tumor cells and circulating tumor DNA: challenges and opportunities on the path to clinical utility. Clin Cancer Res 21 (2015), 4786–4800.
8. [8] Wang, Y., Waters, J., Leung, M.L., Unruh, A., Roh, W., Shi, X., et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 512 (2014), 155–160.
9. [9] Hiley, C., Bruin, E.C.D., Mcgranahan, N., Swanton, C., Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. Genome Biol 15 (2014), 1–10.
10. [10] Crowley, E., Di Nicolantonio, F., Loupakis, F., Bardelli, A., Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 10 (2013), 472–484.
11. [11] Alix-Panabieres, C., Pantel, K., Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discovery 6 (2016), 479–491.
12. [12] Diaz, L.A. Jr., Bardelli, A., Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 32 (2014), 579–586.
13. [13] Leung, F., Kulasingam, V., Diamandis, E.P., Hoon, D.S., Kinzler, K., Pantel, K., et al. Circulating tumor DNA as a cancer biomarker: fact or fiction?. Clin Chem 62 (2016), 1054–1060.
14. [14] Warton, K., Mahon, K.L., Samimi, G., Methylated circulating tumor DNA in blood: power in cancer prognosis and response. Endocr Relat Cancer 23 (2016), R157–R171.
15. [15] Shivapurkar, N., Gazdar, A., DNA methylation based biomarkers in non-invasive cancer screening. Curr Mol Med 10 (2010), 123–132.
16. [16] Cairns, P., Gene methylation and early detection of genitourinary cancer: the road ahead. Nat Rev Cancer 7 (2007), 531–543.
17. [17] Chimonidou, M., Strati, A., Tzitzira, A., Sotiropoulou, G., Malamos, N., Georgoulias, V., et al. DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. Clin Chem 57 (2011), 1169–1177.
18. [18] Dulaimi, E., Hillinck, J., Ibanez de Caceres, I., Al-Saleem, T., Cairns, P., Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res 10 (2004), 6189–6193.
19. [19] Hendee, W.R., Edwards, F.M., Health effects of exposure to low-level ionizing radiation. Acta Radiol 39 (1998), 453–454.
20. [20] Morgan, W.F., Sowa, M.B., Non-targeted effects induced by ionizing radiation: mechanisms and potential impact on radiation induced health effects. Cancer Lett 356 (2015), 17–21.
21. [21] Cho, S.H., Krishnan, S., Cancer nanotechnology: principles and applications in radiation oncology. 2013, CRC Press, Boca Raton, FL.
22. [22] Dechet, C.B., Sebo, T., Farrow, G., Blute, M.L., Engen, D.E., Zincke, H., Prospective analysis of intraoperative frozen needle biopsy of solid renal masses in adults. J Urol 162 (1999), 1282–1284.
23. [23] Al-Leswas, D., O'Reilly, D.A., Poston, G.J., Biopsy of solid liver tumors: adverse consequences. Hepatobiliary Pancreat Dis Int 7 (2008), 325–327.
24. [24] Yang, Y., Li, L., Qu, C., Liang, S., Zeng, B., Luo, Z., Endoscopic ultrasound-guided fine needle core biopsy for the diagnosis of pancreatic malignant lesions: a systematic review and meta-analysis. Sci Rep, 6, 2016, 22978.
25. [25] Hompes, D., Ruers, T., Review: incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer. Eur J Surg Oncol 37 (2011), 737–746.
26. [26] Mazzucchelli, R., Colanzi, P., Pomante, R., Muzzonigro, G., Montironi, R., Prostate tissue and serum markers. Adv Clin Pathol 4 (2000), 111–120.
27. [27] Ruibal, Morell A., CEA serum levels in non-neoplastic disease. Int J Biol Markers 7 (1992), 160–166.
28. [28] Sikaris, K.A., CA125 – a test with a change of heart. Heart Lung Circ 20 (2011), 634–640.
29. [29] Heitzer, E., Auer, M., Ulz, P., Geigl, J.B., Speicher, M.R., Circulating tumor cells and DNA as liquid biopsies. Genome Med 5 (2013), 1–11.
30. [30] Schwarzenbach, H., Hoon, D.S., Pantel, K., Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11 (2011), 426–437.
31. [31] Heitzer, E., Ulz, P., Geigl, J.B., Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem 61 (2015), 112–123.
32. [32] Vickers, K.C., Palmisano, B.T., Shoucri, B.M., Shamburek, R.D., Remaley, A.T., MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13 (2011), 423–433.
33. [33] Giovannetti, E., van der Velde, A., Funel, N., Vasile, E., Perrone, V., Leon, L.G., et al. High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer. PLoS One, 7, 2012, e49145.
34. [34] Wang, Y., Gu, J., Roth, J.A., Hildebrandt, M.A., Lippman, S.M., Ye, Y., et al. Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer. Cancer Res 73 (2013), 4801–4809.
35. [35] Bang, C., Thum, T., Exosomes: new players in cell-cell communication. Int J Biochem Cell Biol 44 (2012), 2060–2064.
36. [36] Simpson, R.J., Lim, J.W., Moritz, R.L., Mathivanan, S., Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics 6 (2009), 267–283.
37. [37] Thakur, B.K., Zhang, H., Becker, A., Matei, I., Huang, Y., Costa-Silva, B., et al. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res 24 (2014), 766–769.
38. [38] Dienstmann, R., Rodon, J., Tabernero, J., Optimal design of trials to demonstrate the utility of genomically-guided therapy: putting precision cancer medicine to the test. Mol Oncol 9 (2015), 940–950.
39. [39] Arnedos, M., Vicier, C., Loi, S., Lefebvre, C., Michiels, S., Bonnefoi, H., et al. Precision medicine for metastatic breast cancer-limitations and solutions. Nat Rev Clin Oncol 12 (2015), 693–704.
40. [40] Baccelli, I., Schneeweiss, A., Riethdorf, S., Stenzinger, A., Schillert, A., Vogel, V., et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 31 (2013), 539–544.
41. [41] Heitzer, E., Ulz, P., Belic, J., Gutschi, S., Quehenberger, F., Fischereder, K., et al. Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med, 5, 2013, 30.
42. [42] Hodgkinson, C.L., Morrow, C.J., Li, Y., Metcalf, R.L., Rothwell, D.G., Trapani, F., et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med 20 (2014), 897–903.
43. [43] Alix-Panabieres, C., Pantel, K., Challenges in circulating tumour cell research. Nat Rev Cancer 14 (2014), 623–631.
44. [44] Ashworth, T.R., A case of cancer in which cells similar to those in the tumors were seen in the blood after death. Aust Med J 14 (1869), 146–147.
45. [45] Krishnamurthy, S., The emerging role of circulating tumor cells in breast cancer. Cancer Cytopathol 120 (2012), 161–166.
46. [46] Hu, B., Rochefort, H., Goldkorn, A., Circulating tumor cells in prostate cancer. Cancers (Basel) 5 (2013), 1676–1690.
47. [47] Schölch, S., Bork, U., Rahbari, N.N., García, S., Swiersy, A., Betzler, A.M., et al. Circulating tumor cells of colorectal cancer. Cancer Cell Microenviron, 1, 2014, e323.
48. [48] Pantel, K., Brakenhoff, R.H., Brandt, B., Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8 (2008), 329–340.
49. [49] Riethdorf, S., Fritsche, H., Muller, V., Rau, T., Schindlbeck, C., Rack, B., et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the cell search system. Clin Cancer Res 13 (2007), 920–928.
50. [50] Nagrath, S., Sequist, L.V., Maheswaran, S., Bell, D.W., Irimia, D., Ulkus, L., et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450 (2007), 1235–1239.
51. [51] Issadore, D., Chung, J., Shao, H., Liong, M., Ghazani, A.A., Castro, C.M., et al. Ultrasensitive clinical enumeration of rare cells ex vivo using a micro-hall detector. Sci Transl Med, 4, 2012, 141ra92.
52. [52] Karabacak, N.M., Spuhler, P.S., Fachin, F., Lim, E.J., Pai, V., Ozkumur, E., et al. Microfluidic, marker-free isolation of circulating tumor cells from blood samples. Nat Protoc 9 (2014), 694–710.
53. [53] Dawson, S.J., Tsui, D.W., Murtaza, M., Biggs, H., Rueda, O.M., Chin, S.F., et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368 (2013), 1199–1209.
54. [54] Siravegna, G., Bardelli, A., Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients. Mol Oncol 10 (2016), 475–480.
55. [55] Mabert, K., Cojoc, M., Peitzsch, C., Kurth, I., Souchelnytskyi, S., Dubrovska, A., Cancer biomarker discovery: current status and future perspectives. Int J Radiat Biol 90 (2014), 659–677.
56. [56] Mandel, P., Metais, P., Les acides nucleiques du plasma sanguin chez l'homme. CR Acad Sci Paris 142 (1948), 241–243.
57. [57] Leon, S.A., Shapiro, B., Sklaroff, D.M., Yaros, M.J., Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37 (1977), 646–650.
58. [58] Stroun, M., Anker, P., Maurice, P., Lyautey, J., Lederrey, C., Beljanski, M., Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 46 (1989), 318–322.
59. [59] Vasioukhin, V., Anker, P., Maurice, P., Lyautey, J., Lederrey, C., Stroun, M., Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol 86 (1994), 774–779.
60. [60] Fujiwara, K., Fujimoto, N., Tabata, M., Nishii, K., Matsuo, K., Hotta, K., et al. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res 11 (2005), 1219–1225.
61. [61] Hardy, T., Zeybel, M., Day, C.P., Dipper, C., Masson, S., McPherson, S., et al. Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease. Gut, 2016 http://www.idf.org/gutjnl-2016-311526.
62. [62] Jovelet, C., Ileana, E., Le Deley, M.C., Motte, N., Rosellini, S., Romero, A., et al. Circulating cell-free tumor DNA analysis of 50 genes by next-generation sequencing in the prospective MOSCATO trial. Clin Cancer Res 22 (2016), 2960–2968.
63. [63] Cheng, F., Su, L., Qian, C., Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget 7 (2016), 48832–48841.
64. [64] Diehl, F., Schmidt, K., Choti, M.A., Romans, K., Goodman, S., Li, M., et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 14 (2008), 985–990.
65. [65] Sun, K., Jiang, P., Chan, K.C., Wong, J., Cheng, Y.K., Liang, R.H., et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci U S A 112 (2015), E5503–E5512.
66. [66] Jahr, S., Hentze, H., Englisch, S., Hardt, D., Fackelmayer, F.O., Hesch, R.D., et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61 (2001), 1659–1665.
67. [67] Fleischhacker, M., Schmidt, B., Circulating nucleic acids (CNAs) and cancer – a survey. Biochim Biophys Acta 1775 (2007), 181–232.
68. [68] Bettegowda, C., Sausen, M., Leary, R.J., Kinde, I., Wang, Y., Agrawal, N., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med, 6, 2014, 224ra24.
69. [69] Gold, B., Cankovic, M., Furtado, L.V., Meier, F., Gocke, C.D., Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility?. J Mol Diagn 17 (2015), 209–224.
70. [70] Jiang, P., Chan, C.W., Chan, K.C., Cheng, S.H., Wong, J., Wong, V.W., et al. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci U S A 112 (2015), E1317–E1325.
71. [71] Huang, Z., Hua, D., Hu, Y., Cheng, Z., Zhou, X., Xie, Q., et al. Quantitation of plasma circulating DNA using quantitative PCR for the detection of hepatocellular carcinoma. Pathol Oncol Res 18 (2012), 271–276.
72. [72] Hoque, M.O., Feng, Q., Toure, P., Dem, A., Critchlow, C.W., Hawes, S.E., et al. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol 24 (2006), 4262–4269.
73. [73] Webb, S., The cancer bloodhounds. Nat Biotechnol 34 (2016), 1090–1094.
74. [74] Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C., Parkin, D.M., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127 (2010), 2893–2917.
75. [75] Shaw, J.A., Page, K., Blighe, K., Hava, N., Guttery, D., Ward, B., et al. Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. Genome Res 22 (2012), 220–231.
76. [76] Shah, S.S., Ketterling, R.P., Goetz, M.P., Ingle, J.N., Reynolds, C.A., Perez, E.A., et al. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer. Hum Pathol 41 (2010), 103–106.
77. [77] Higgins, M.J., Jelovac, D., Barnathan, E., Blair, B., Slater, S., Powers, P., et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res 18 (2012), 3462–3469.
78. [78] Gevensleben, H., Garcia-Murillas, I., Graeser, M.K., Schiavon, G., Osin, P., Parton, M., et al. Noninvasive detection of HER2 amplification with plasma DNA digital PCR. Clin Cancer Res 19 (2013), 3276–3284.
79. [79] Beaver, J.A., Jelovac, D., Balukrishna, S., Cochran, R.L., Croessmann, S., Zabransky, D.J., et al. Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res 20 (2014), 2643–2650.
80. [80] Chu, D., Paoletti, C., Gersch, C., VanDenBerg, D.A., Zabransky, D.J., Cochran, R.L., et al. ESR1 mutations in circulating plasma tumor DNA from metastatic breast cancer patients. Clin Cancer Res 22 (2016), 993–999.
81. [81] De Mattos-Arruda, L., Cortes, J., Santarpia, L., Vivancos, A., Tabernero, J., Reis-Filho, J.S., et al. Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol 10 (2013), 377–389.
82. [82] Olsson, E., Winter, C., George, A., Chen, Y., Howlin, J., Tang, M.H., et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med 7 (2015), 1034–1047.
83. [83] Kamel, A.M., Teama, S., Fawzy, A., El Deftar, M., Plasma DNA integrity index as a potential molecular diagnostic marker for breast cancer. Tumour Biol 37 (2016), 7565–7572.
84. [84] Madic, J., Kiialainen, A., Bidard, F.C., Birzele, F., Ramey, G., Leroy, Q., et al. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. Int J Cancer 136 (2015), 2158–2165.
85. [85] Liggett, T.E., Melnikov, A.A., Marks, J.R., Levenson, V.V., Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients. Int J Cancer 128 (2011), 492–499.
86. [86] Fiegl, H., Millinger, S., Mueller-Holzner, E., Marth, C., Ensinger, C., Berger, A., et al. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 65 (2005), 1141–1145.
87. [87] Fu, D., Ren, C., Tan, H., Wei, J., Zhu, Y., He, C., et al. Sox17 promoter methylation in plasma DNA is associated with poor survival and can be used as a prognostic factor in breast cancer. Medicine (Baltimore), 94, 2015, e637.
88. [88] Wittenberger, T., Sleigh, S., Reisel, D., Zikan, M., Wahl, B., Alunni-Fabbroni, M., et al. DNA methylation markers for early detection of women's cancer: promise and challenges. Epigenomics 6 (2014), 311–327.
89. [89] Avraham, A., Uhlmann, R., Shperber, A., Birnbaum, M., Sandbank, J., Sella, A., et al. Serum DNA methylation for monitoring response to neoadjuvant chemotherapy in breast cancer patients. Int J Cancer 131 (2012), E1166–E1672.
90. [90] Yamamoto, N., Nakayama, T., Kajita, M., Miyake, T., Iwamoto, T., Kim, S.J., et al. Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARbeta2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay. Breast Cancer Res Treat 132 (2012), 165–173.
91. [91] Mirza, S., Sharma, G., Parshad, R., Srivastava, A., Gupta, S.D., Ralhan, R., Clinical significance of promoter hypermethylation of ERbeta and RARbeta2 in tumor and serum DNA in Indian breast cancer patients. Ann Surg Oncol 19 (2012), 3107–3115.
92. [92] Li, Z., Guo, X.W., Tang, L.L., Peng, L.M., Chen, M., Luo, X.P., et al. Methylation analysis of plasma cell-free DNA for breast cancer early detection using bisulfite next-generation sequencing. Tumor Biol 37 (2016), 13111–13119.
93. [93] Siegel, R., Desantis, C., Jemal, A., Colorectal cancer statistics, 2014. CA Cancer J Clin 64 (2014), 104–117.
94. [94] Diaz, L.A. Jr., Williams, R.T., Wu, J., Kinde, I., Hecht, J.R., Berlin, J., et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486 (2012), 537–540.
95. [95] Siravegna, G., Mussolin, B., Buscarino, M., Corti, G., Cassingena, A., Crisafulli, G., et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med, 21, 2015, 827.
96. [96] Spindler, K.L., Pallisgaard, N., Vogelius, I., Jakobsen, A., Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res 18 (2012), 1177–1185.
97. [97] Spindler, K.L., Sorensen, M.M., Pallisgaard, N., Andersen, R.F., Havelund, B.M., Ploen, J., et al. Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma. Acta Oncol 52 (2013), 963–970.
98. [98] Wang, J.Y., Hsieh, J.S., Chang, M.Y., Huang, T.J., Chen, F.M., Cheng, T.L., et al. Molecular detection of APC, K-ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J Surg 28 (2004), 721–726.
99. [99] Tie, J., Kinde, I., Wang, Y., Wong, H.L., Roebert, J., Christie, M., et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol 26 (2015), 1715–1722.
100. [100] Kidess, E., Heirich, K., Wiggin, M., Vysotskaia, V., Visser, B.C., Marziali, A., et al. Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform. Oncotarget 6 (2015), 2549–2561.
101. [101] Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486 (2012), 532–536.
102. [102] Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discovery 3 (2013), 658–673.
103. [103] Misale, S., Arena, S., Lamba, S., Siravegna, G., Lallo, A., Hobor, S., et al. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med, 6, 2014, 162ra54.
104. [104] Mohan, S., Heitzer, E., Ulz, P., Lafer, I., Lax, S., Auer, M., et al. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLoS Genet, 10, 2014, e1004271.
105. [105] Johnson, V., Volikos, E., Halford, S.E., Eftekhar Sadat, E.T., Popat, S., Talbot, I., et al. Exon 3 beta-catenin mutations are specifically associated with colorectal carcinomas in hereditary non-polyposis colorectal cancer syndrome. Gut 54 (2005), 264–267.
106. [106] Ilyas, M., Tomlinson, I.P.M., Rowan, A., Pignatelli, M., Bodmer, W.F., β-Catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci U S A 94 (1997), 10330–10334.
107. [107] Guo, J., Cagatay, T., Zhou, G., Chan, C.C., Blythe, S., Suyama, K., et al. Mutations in the human naked cuticle homolog NKD1 found in colorectal cancer alter Wnt/Dvl/beta-catenin signaling. PLoS One 4 (2009), 1493–1494.
108. [108] Powrozek, T., Krawczyk, P., Kucharczyk, T., Milanowski, J., Septin 9 promoter region methylation in free circulating DNA-potential role in noninvasive diagnosis of lung cancer: preliminary report. Med Oncol, 31, 2014, 917.
109. [109] Pack, S.C., Kim, H.R., Lim, S.W., Kim, H.Y., Ko, J.Y., Lee, K.S., et al. Usefulness of plasma epigenetic changes of five major genes involved in the pathogenesis of colorectal cancer. Int J Colorectal Dis 28 (2013), 139–147.
110. [110] Grawenda, A.M., O'Neill, E., Clinical utility of RASSF1A methylation in human malignancies. Br J Cancer 113 (2015), 372–381.
111. [111] Zhang, Z., Lee, J.C., Lin, L., Olivas, V., Au, V., LaFramboise, T., et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44 (2012), 852–860.
112. [112] Bai, H., Wang, Z., Chen, K., Zhao, J., Lee, J.J., Wang, S., et al. Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol 30 (2012), 3077–3083.
113. [113] Akca, H., Demiray, A., Yaren, A., Bir, F., Koseler, A., Iwakawa, R., et al. Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer. Cancer Genet 206 (2013), 73–80.
114. [114] Leary, R.J., Sausen, M., Kinde, I., Papadopoulos, N., Carpten, J.D., Craig, D., et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med, 4, 2012, 162ra54.
115. [115] Narayan, A., Carriero, N.J., Gettinger, S.N., Kluytenaar, J., Kozak, K.R., Yock, T.I., et al. Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. Cancer Res 72 (2012), 3492–3498.
116. [116] Vinayanuwattikun, C., Sriuranpong, V., Tanasanvimon, S., Chantranuwat, P., Mutirangura, A., Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer. J Thorac Oncol 6 (2011), 1818–1825.
117. [117] Jiao, L., Zhu, J., Hassan, M.M., Evans, D.B., Abbruzzese, J.L., Li, D., K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking. Pancreas 34 (2007), 55–62.
118. [118] He, W.S., Bishop, K.S., The potential use of cell-free-circulating-tumor DNA as a biomarker for prostate cancer. Expert Rev Mol Diagn 16 (2016), 839–852.
119. [119] Cherepanova, A.V., Tamkovich, S.N., Bryzgunova, O.E., Vlassov, V.V., Laktionov, P.P., Deoxyribonuclease activity and circulating DNA concentration in blood plasma of patients with prostate tumors. Ann NY Acad Sci 1137 (2008), 218–221.
120. [120] Delgado, P.O., Alves, B.C., Gehrke Fde, S., Kuniyoshi, R.K., Wroclavski, M.L., Del Giglio, A., et al. Characterization of cell-free circulating DNA in plasma in patients with prostate cancer. Tumour Biol 34 (2013), 983–986.
121. [121] Kinde, I., Bettegowda, C., Wang, Y., Wu, J., Agrawal, N., Shih Ie, M., et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med, 5, 2013, 167ra4.
122. [122] Murtaza, M., Dawson, S.J., Tsui, D.W., Gale, D., Forshew, T., Piskorz, A.M., et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497 (2013), 108–112.
123. [123] Sikora, K., Bedin, C., Vicentini, C., Malpeli, G., D'Angelo, E., Sperandio, N., et al. Evaluation of cell-free DNA as a biomarker for pancreatic malignancies. Int J Biol Markers 30 (2015), e136–e141.
124. [124] Laird, P.W., The power and the promise of DNA methylation markers. Nat Rev Cancer 3 (2003), 253–266.
125. [125] Feinberg, A., DNA methylation in cancer: three decades of discovery. Genome Med 6 (2014), 1–4.
126. [126] Jin, H., Ma, Y., Shen, Q., Wang, X., Circulating methylated DNA as biomarkers for cancer detection. methylation-from DNA, RNA and histones to diseases and treatment. Intech, 2013, 137–152.
127. [127] Miotto, E., Sabbioni, S., Veronese, A., Calin, G.A., Gullini, S., Liboni, A., et al. Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer. Cancer Res 64 (2004), 8156–8159.
128. [128] Grady, W.M., Rajput, A., Lutterbaugh, J.D., Markowitz, S.D., Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res 61 (2001), 900–902.
129. [129] Zou, H.Z., Yu, B.M., Wang, Z.W., Sun, J.Y., Cai, H., Gao, F., et al. Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin Cancer Res 8 (2002), 188–191.
130. [130] Lecomte, T., Berger, A., Zinzindohoue, F., Micard, S., Landi, B., Blons, H., et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer 100 (2002), 542–548.
131. [131] Ebert, M.P., Model, F., Mooney, S., Hale, K., Lograsso, J., Tonnes-Priddy, L., et al. Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas. Gastroenterology 131 (2006), 1418–1430.
132. [132] Lofton-Day, C., Model, F., Devos, T., Tetzner, R., Distler, J., Schuster, M., et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem 54 (2008), 414–423.
133. [133] Warren, J.D., Xiong, W., Bunker, A.M., Vaughn, C.P., Furtado, L.V., Roberts, W.L., et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med, 9, 2011, 133.
134. [134] De Vos, T., Tetzner, R., Model, F., Weiss, G., Schuster, M., Distler, J., et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem 55 (2009), 1337–1346.
135. [135] Silva, J., Dominguez, G., Gonzalez, R., Garcia, J., Corbacho, C., Provencio, M., et al. Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients. Br J Cancer 80 (1999), 1262–1264.
136. [136] Esteller, M., Sanchez-Cespedes, M., Rosell, R., Sidransky, D., Baylin, S.B., Herman, J.G., Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 59 (1999), 67–70.
137. [137] El Messaoudi, S., Rolet, F., Mouliere, F., Thierry, A.R., Circulating cell free DNA: preanalytical considerations. Clin Chim Acta 424 (2013), 222–230.
138. [138] Wang, W.Y., Barratt, B.J., Clayton, D.G., Todd, J.A., Genome-wide association studies: theoretical and practical concerns. Nat Rev Genet 6 (2005), 109–118.
139. [139] Xu, J., Mo, Z., Ye, D., Wang, M., Liu, F., Jin, G., et al. Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4. Nat Genet 44 (2012), 1231–1235.
140. [140] Forshew, T., Murtaza, M., Parkinson, C., Gale, D., Tsui, D.W.Y., Kaper, F., et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med, 4, 2012, 136ra68.
141. [141] Ashida, A., Sakaizawa, K., Mikoshiba, A., Uhara, H., Okuyama, R., Quantitative analysis of the BRAF mutation in circulating tumor-derived DNA in melanoma patients using competitive allele-specific TaqMan PCR. Int J Clin Oncol 21 (2016), 981–988.
142. [142] Hindson, C.M., Chevillet, J.R., Briggs, H.A., Gallichotte, E.N., Ruf, I.K., Hindson, B.J., et al. Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods 10 (2013), 1003–1005.
143. [143] Newman, A.M., Bratman, S.V., To, J., Wynne, J.F., Eclov, N.C., Modlin, L.A., et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 20 (2014), 548–554.
144. [144] Bratman, S.V., Newman, A.M., Alizadeh, A.A., Diehn, M., Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq. Expert Rev Mol Diagn 15 (2015), 715–719.
145. [145] Newman, A.M., Lovejoy, A.F., Klass, D.M., Kurtz, D.M., Chabon, J.J., Scherer, F., et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol 34 (2016), 547–555.
146. [146] Chan, K.C., Jiang, P., Zheng, Y.W., Liao, G.J., Sun, H., Wong, J., et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem 59 (2013), 211–224.
147. [147] Vogelstein, B., Kinzler, K.W., Digital PCR. Proc Natl Acad Sci U S A 96 (1999), 9236–9241.
148. [148] Gray, E.S., Rizos, H., Reid, A.L., Boyd, S.C., Pereira, M.R., Lo, J., et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget 6 (2015), 42008–42018.
149. [149] Tsao, S.C., Weiss, J., Hudson, C., Christophi, C., Cebon, J., Behren, A., et al. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations. Sci Rep, 5, 2015, 11198.
150. [150] Huang, A., Zhang, X., Zhou, S.L., Cao, Y., Huang, X.W., Fan, J., et al. Detecting circulating tumor DNA in hepatocellular carcinoma patients using droplet digital PCR is feasible and reflects intratumoral heterogeneity. J Cancer 7 (2016), 1907–1914.
151. [151] Laurent-Puig, P., Pekin, D., Normand, C., Kotsopoulos, S.K., Nizard, P., Perez-Toralla, K., et al. Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy. Clin Cancer Res 21 (2015), 1087–1097.
152. [152] Denis, J.A., Patroni, A., Guillerm, E., Pépin, D., Benali-Furet, N., Wechsler, J., et al. Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict KRAS mutations before surgery. Mol Oncol 10 (2016), 1221–1231.
153. [153] Mishima, C., Kagara, N., Matsui, S., Tanei, T., Naoi, Y., Shimoda, M., et al. Promoter methylation of TRIM9 as a marker for detection of circulating tumor DNA in breast cancer patients. Springerplus, 4, 2015, 635.
154. [154] Balgkouranidou, I., Chimonidou, M., Milaki, G., Tsaroucha, E., Kakolyris, S., Georgoulias, V., et al. SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer. Clin Chem Lab Med 54 (2016), 1385–1393.
155. [155] Wang, J., Qin, Y., Li, B., Sun, Z., Yang, B., Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients. Clin Biochem 39 (2006), 344–348.
156. [156] Feehery GR, Pradhan S. Method for enriching methylated CpG sequences. US Patent Application 2013;US8367331.
157. [157] Herman, J.G., Graff, J.R., Myöhänen, S., Nelkin, B.D., Baylin, S.B., Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93 (1996), 9821–9826.
158. [158] Licchesi, J.D., Herman, J.G., Methylation-specific PCR. Methods Mol Biol 507 (2009), 305–323.
159. [159] Kimler, B., Fackler, M.J., Metheny, T., Phillips, T., Sukumar, S., Fabian, C., Consistency of quantitative multiplexed – methylation specific PCR (QM-MSP) performed on breast epithelial cells acquired by random periareolar fine needle aspiration (RPFNA) of women at high risk for development of breast cancer. Cancer Res, 67, 2007.
160. [160] Bailey, V.J., Zhang, Y., Keeley, B.P., Yin, C., Pelosky, K.L., Brock, M., et al. Single-tube analysis of DNA methylation with silica superparamagnetic beads. Clin Chem 56 (2010), 1022–1025.
161. [161] Wong, I.H., Lo, Y.M., Zhang, J., Liew, C.T., Ng, M.H., Wong, N., et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res 59 (1999), 71–73.
162. [162] Eads, C.A., Danenberg, K.D., Kawakami, K., Saltz, L.B., Blake, C., Shibata, D., et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucl Acids Res, 28, 2000, E32.
163. [163] Bailey, V.J., Keeley, B.P., Zhang, Y., Ho, Y.P., Easwaran, H., Brock, M.V., et al. Enzymatic incorporation of multiple dyes for increased sensitivity in QD-FRET sensing for DNA methylation detection. ChemBioChem 11 (2010), 71–74.
164. [164] Guzzetta, A.A., Pisanic Ii, T.R., Sharma, P., Yi, J.M., Stark, A., Wang, T.H., et al. The promise of methylation on beads for cancer detection and treatment. Expert Rev Mol Diagn 14 (2014), 845–852.
165. [165] Fackler, M.J., Lopez Bujanda, Z., Umbricht, C., Teo, W.W., Cho, S., Zhang, Z., et al. Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. Cancer Res 74 (2014), 2160–2170.
166. [166] Li, Y., Zhu, J., Geng, T., Ning, L., Li, Q., Ye, M., et al. The DNA methylome of human peripheral blood mononuclear cells. PLoS Biol 8 (2010), 549–552.
167. [167] Urich, M.A., Nery, J.R., Lister, R., Schmitz, R.J., Ecker, J.R., MethylC-seq library preparation for base-resolution whole-genome bisulfite sequencing. Nat Protoc 10 (2015), 475–483.
168. [168] Smith, Z.D., Gu, H.C., Bock, C., Gnirke, A., Meissner, A., High-throughput bisulfite sequencing in mammalian genomes. Methods 48 (2009), 226–232.
169. [169] Serre, D., Lee, B.H., Ting, A.H., MBD-isolated genome sequencing provides a high-throughput and comprehensive survey of DNA methylation in the human genome. Nucl Acids Res 38 (2010), 391–399.
170. [170] Clark, C., Palta, P., Joyce, C.J., Scott, C., Grundberg, E., Deloukas, P., et al. A comparison of the whole genome approach of MeDIP-Seq to the targeted approach of the infinium humanmethylation450 BeadChip® for methylome profiling. PLoS One, 7, 2012, e50233.
171. [171] Taiwo, O., Wilson, G.A., Morris, T., Seisenberger, S., Reik, W., Pearce, D., et al. Methylome analysis using MeDIP-seq with low DNA concentrations. Nat Protoc 7 (2012), 617–636.
172. [172] Chan, K.C., Jiang, P., Chan, C.W., Sun, K., Wong, J., Hui, E.P., et al. Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. Proc Natl Acad Sci U S A 110 (2013), 18761–18768.
173. [173] Wen, L., Li, J., Guo, H., Liu, X., Zheng, S., Zhang, D., et al. Genome-scale detection of hypermethylated CpG islands in circulating cell-free DNA of hepatocellular carcinoma patients. Cell Res 25 (2015), 1250–1264.
174. [174] Rand, K., Qu, W., Ho, T., Clark, S.J., Molloy, P., Conversion-specific detection of DNA methylation using real-time polymerase chain reaction (ConLight-MSP) to avoid false positives. Methods 27 (2002), 114–120.
175. [175] Ilie, M., Hofman, V., Long, E., Bordone, O., Selva, E., Washetine, K., et al. Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine?. Ann Transl Med, 2, 2014, 107.
176. [176] Gormally, E., Caboux, E., Vineis, P., Hainaut, P., Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res 635 (2007), 105–117.
177. [177] Schwarzenbach, H., Muller, V., Milde-Langosch, K., Steinbach, B., Pantel, K., Evaluation of cell-free tumour DNA and RNA in patients with breast cancer and benign breast disease. Mol Biosyst 7 (2011), 2848–2854.
178. [178] Park, J.L., Kim, H.J., Choi, B.Y., Lee, H.C., Jang, H.R., Song, K.S., et al. Quantitative analysis of cell-free DNA in the plasma of gastric cancer patients. Oncol Lett 3 (2012), 921–926.
179. [179] Salvianti, F., Pinzani, P., Verderio, P., Ciniselli, C.M., Massi, D., De Giorgi, V., et al. Multiparametric analysis of cell-free DNA in melanoma patients. PLoS One, 7, 2012, e49843.
180. [180] Ha, T.T., Huy, N.T., Murao, L.A., Lan, N.T., Thuy, T.T., Tuan, H.M., et al. Elevated levels of cell-free circulating DNA in patients with acute dengue virus infection. PLoS One, 6, 2011, e25969.
181. [181] Huang, C.H., Tsai, M.S., Hsu, C.Y., Chen, H.W., Wang, T.D., Chang, W.T., et al. Circulating cell-free DNA levels correlate with postresuscitation survival rates in out-of-hospital cardiac arrest patients. Resuscitation 83 (2012), 213–218.
182. [182] Iriyama, C., Tomita, A., Hoshino, H., Adachi-Shirahata, M., Furukawa-Hibi, Y., Yamada, K., et al. Using peripheral blood circulating DNAs to detect CpG global methylation status and genetic mutations in patients with myelodysplastic syndrome. Biochem Biophys Res Commun 419 (2012), 662–669.
183. [183] Kwee, S., Song, M.A., Cheng, I., Loo, L., Tiirikainen, M., Measurement of circulating cell-free DNA in relation to 18F-fluorocholine PET/CT imaging in chemotherapy-treated advanced prostate cancer. Clin Transl Sci 5 (2012), 65–70.
184. [184] Klein, C.A., Parallel progression of primary tumours and metastases. Nat Rev Cancer 9 (2009), 302–312.
185. [185] Ma, M., Zhu, H., Zhang, C., Sun, X., Gao, X., Chen, G., “Liquid biopsy”-ctDNA detection with great potential and challenges. Ann Transl Med, 3, 2015, 235.
186. [186] Pan, H., Chen, L., Dogra, S., Teh, A.L., Tan, J.H., Lim, Y.I., et al. Measuring the methylome in clinical samples: improved processing of the infinium human methylation450 beadchip array. Epigenetics 7 (2012), 1173–1187.
187. [187] Mack, S.C., Witt, H., Piro, R.M., Gu, L., Zuyderduyn, S., Stutz, A.M., et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 506 (2014), 445–450.
188. [188] Hudecova, I., Digital PCR analysis of circulating nucleic acids. Clin Biochem 48 (2015), 948–956.
189. [189] Jansen, M., Martens, J., Helmijr, J., Beaufort, C., Van, M., Krol, N., et al. Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen. Oncotarget 7 (2016), 43412–43418.
190. [190] Souverijn, J.H., Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med, 371, 2014, 187.
191. [191] Church, T.R., Wandell, M., Lofton-Day, C., Mongin, S.J., Burger, M., Payne, S.R., et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 63 (2014), 317–325.
192. [192] Ilse, P., Biesterfeld, S., Pomjanski, N., Wrobel, C., Schramm, M., Analysis of SHOX2 methylation as an aid to cytology in lung cancer diagnosis. Cancer Genomics Proteomics 11 (2014), 251–258.
193. [193] Brown, P., The Cobas(®) EGFR mutation test v2 assay. Future Oncol 12 (2016), 451–452.
194. [194] Kopreski, M., Benko, F., Kwee, C., Leitzel, K., Eskander, E., Lipton, A., et al. Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer. Br J Cancer, 76, 1997, 1293.
195. [195] Yamada, T., Nakamori, S., Ohzato, H., Oshima, S., Aoki, T., Higaki, N., et al. Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. Clin Cancer Res 4 (1998), 1527–1532.
196. [196] Sanchez-Cespedes, M., Monzo, M., Rosell, R., Pifarre, A., Calvo, R., Lopez-Cabrerizo, M.P., et al. Detection of chromosome 3p alterations in serum DNA of non-small-cell lung cancer patients. Ann Oncol 9 (1998), 113–116.